| 饶晓明,李海燕,李凯.抗非小细胞肺癌药物奥希替尼研究进展[J].安徽医药,2019,23(3):611-614. |
| 抗非小细胞肺癌药物奥希替尼研究进展 |
| Research progress of osimertinib for NSCLC |
| 投稿时间：2017-08-26 |
| DOI： |
| 中文关键词: 奥希替尼 非小细胞肺癌 EGFR-TKI 研究进展 |
| 英文关键词: Osimertinib Non-small cell lung cancer(NSCLC) EGFR-TKI Research progress |
| 基金项目: |
|
| 摘要点击次数: 3609 |
| 全文下载次数: 716 |
| 中文摘要: |
| 年3月22日中国食品药品监督管理局(CFDA)批准表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)奥希替尼(Osimertinib)用于治疗EGFR T790M基因突变阳性的局部晚期或转移性非小细胞肺癌(NSCLC)。奥希替尼是第三代EGFR-TKI,治疗效果显著,副作用更小,尤其适用于对第一、二代EGFR-TKI耐药或者脑转移的病人。与含铂类治疗药物的二联化学疗法相比,奥希替尼可使NSCLC病人中位无进展生存期(PFS)延长5.7个月,疾病进展风险下降70%。该文就奥希替尼的作用机制、研究历程、药效学、药动学、不良反应,耐药机制进行综述,为临床使用提供参考。 |
| 英文摘要: |
| On March 22,7,CFDA approved Osimertinib which is a epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) to treat EGFR T790M gene mutation positive of locally advanced or metastatic non-small-cell lung cancer (NSCLC).Osimertinib is a third-generation EGFR-TKI with highly effective treatment and few side effects,especially suitable for the first and the second generation of EGFR-TKI resistance or patients with brain metastases.Compared with platinum-based duplex chemical therapy,the median duration of progression-free survival(PFS) of Osimertinib extend for 5.7 months and its disease progression risk reduce to 70%.In this paper,we review the Osimertinib of its mechanism of action,research history,pharmacodynamics,pharmacokinetics,side effects,resistance mechanisms in order to provide reference for clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
